D18

D18 is an immune modulator. D18 acts as a TLR7/8 dual agonist (EC50 = 24 nM for hTLR7 and 10 nM for hTLR8, respectively) . D18 increases PD-L1 expression through epigenetic regulation, thus sensitizing tumors to PD-1/PD-L1 blockade. D18 is a ADC cytotoxin uesd for the systhesis of ADC HE-S2 (HY-144497) . D18 has strong immune activation and anti-tumor activity. D18 commonly used in cancer research, such as colon cancer[1][2].

Product Specifications

CAS Number

[2230218-36-5]

UNSPSC

12352005

Target

PD-1/PD-L1; Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/d18.html

Purity

98.79

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

NC(N=C1NCCCC)=NC(C1=N2)=CC=C2CC(C=C3)=CC=C3CN(C)C

Molecular Formula

C21H28N6

Molecular Weight

364.49

References & Citations

[1]He L, et al. Immune Modulating Antibody-Drug Conjugate (IM-ADC) for Cancer Immunotherapy. J Med Chem. 2021;64 (21) :15716-15726. |[2]Wang Z, et al. Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy. J Med Chem. 2021 Jun 10;64 (11) :7507-7532.